Ivana Sullivan
Clinical Research Medical Director Amgen Inc.
Seminars
Tuesday 8th September 2026
Advancing First Line Care for KRAS G12C positive & PD L1 negative NSCLC: Optimizing Targeted Therapy + Chemotherapy for a High-Unmet- Need Population
2:30 pm
- Highlighting the distinct clinical profile and poor real world outcomes of KRAS G12C +ve / PD L1 -ve NSCLC, underscoring why this population represents a critical unmet need in first line treatment.
- Demonstrating how a cleaner, biomarker defined trial design and a safer chemo + targeted therapy approach may avoid early immunotherapy related toxicities while preserving future treatment options
- Exploring the role of translational research, including proteomics, transcriptomics, and longitudinal blood sampling, in understanding treatment response, resistance, and sequencing strategies across the patient journey
